Immune-based therapies for hepatocellular carcinoma

Area of Science:

• Hepatobiliary Cancers
• Immunology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a major global cancer burden and the third leading cause of cancer-related mortality.
• The tumor microenvironment in HCC is rich in immune cells, presenting a promising target for immunotherapies.

Purpose of the Study:

• To explore the potential of leveraging the liver microenvironment for HCC treatment.
• To review current evidence for immunotherapeutic strategies in HCC, including vaccines, cell-based therapies, and immune-checkpoint inhibitors.

Main Methods:

• Literature review of existing studies on HCC immunotherapies.
• Analysis of the functional characteristics of the liver microenvironment relevant to immune responses.
• Discussion of patient stratification strategies to improve therapeutic outcomes.

Main Results:

• The immune-rich contexture of HCC suggests significant therapeutic potential for immune-based strategies.
• Evidence supports the role of vaccines, cell-based therapies, and immune-checkpoint inhibitors in HCC treatment.
• Patient stratification may be key to overcoming past drug development failures.

Conclusions:

• The liver microenvironment offers unique opportunities for developing effective HCC immunotherapies.
• Combining different immunotherapeutic approaches and patient selection criteria could enhance treatment efficacy.
• Further research into harnessing immune responses within the liver is crucial for advancing HCC care.